Evidence map›Paper›PMID 41657055›Full record

ArticleBiology open2026

Antibiotics modulate Escherichia coli-derived bacterial extracellular vesicle production and their upregulation of ICAM-1 in human endothelial cells.

Louis P Widom, Panteha Torabian, Abigail C Wojehowski, Sina Ghaemmaghami, Lea V Michel, Thomas R Gaborski

Abstract read
In one paragraph

Article in Biology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Louis P WidomDepartment of Biomedical Engineering, Rochester Institute of Technology, Rochester, NY 14623, USA.ORCID 0000-0002-2492-9004
Panteha TorabianDepartment of Biomedical Engineering, Rochester Institute of Technology, Rochester, NY 14623, USA.ORCID 0009-0006-2163-0564
Abigail C WojehowskiDepartment of Biomedical Engineering, Rochester Institute of Technology, Rochester, NY 14623, USA.
Sina GhaemmaghamiDepartment of Biology, University of Rochester, Rochester, NY 14627, USA.ORCID 0000-0002-8696-2950
Lea V MichelSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY 14623, USA.ORCID 0000-0001-6104-4646
Thomas R GaborskiDepartment of Biomedical Engineering, Rochester Institute of Technology, Rochester, NY 14623, USA.ORCID 0000-0002-3676-3208

Funding

The µSiM-hNVU - a human BBB platform for the study of brain injury mechanisms during systemic infectionR33HL154249 · NHLBI · UNIVERSITY OF ROCHESTER · PI ENGELHARDT, BRITTA, GABORSKI, THOMAS R · 2022 to 2024
$2.2M
Engineering Cell-Substrate Interactions on Porous Membranes to Create Physiologically Relevant Model SystemsR35GM153461 · NIGMS · ROCHESTER INSTITUTE OF TECHNOLOGY · PI THOMAS R GABORSKI · 2024 to 2026
$1.1M
Using nanopocket membranes to capture bacterial outer membrane vesicles from biofluidsR21AI163782 · NIAID · ROCHESTER INSTITUTE OF TECHNOLOGY · PI GABORSKI, THOMAS R, MICHEL, LEA VACCA · 2021 to 2022
$417k
Hank and Lynn Hopeman FoundationNational Institute of Allergy and Infectious DiseasesNHLBI NIH HHS R33 HL154249NHLBI NIH HHS R33HL154249NIAID NIH HHS R21 AI163782NIGMS NIH HHS R35 GM153461NIGMS NIH HHS R35GM153461NIH HHS R21AI163782Rochester Institute of Technology
6 · The paper itself

Abstract

Antibiotic treatment is often necessary to eliminate life-threatening bacterial infections. However, these treatments can alter production of bacterial extracellular vesicles (BEVs), which often contain pro-inflammatory biomolecules. In this study, we examined how the clinically relevant antibiotics meropenem, tobramycin, and ciprofloxacin impacted BEV production from a urinary tract infection-associated Escherichia coli strain (CFT073 [WAM2267]) and a meningitis-associated strain (K1 RS218). BEVs from both strains caused a dose-dependent increase in expression of intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells, priming the endothelium for interactions with immune cells. Blockade of toll-like receptor 4 revealed that this receptor was responsible for BEV-endothelial interactions. Treatment with meropenem, a β-lactam antibiotic, increased production of BEVs from strain K1 RS218. Furthermore, meropenem treatment caused strain CFT073 [WAM2267] to produce BEVs with heightened stimulatory capacity, possibly by amplifying the content of lipoprotein Lpp in these BEVs as measured by mass spectrometry. To our knowledge, this is the first study examining the interplay between antibiotic treatment and the effects of the resulting BEVs on endothelial ICAM-1 expression. Our results indicate treatment risks of certain antibiotics against specific strains of E. coli and could help identify therapeutic targets to reduce BEV-mediated endothelial stimulation during infection.

Indexed as

Anti-Bacterial AgentsEndothelial CellsEscherichia coliExtracellular VesiclesIntercellular Adhesion Molecule-1HumansHuman Umbilical Vein Endothelial CellsUp-RegulationAnti-Bacterial AgentsIntercellular Adhesion Molecule-1AntibioticsBacterial extracellular vesicles (BEVs)Endothelial inflammationEscherichia coliIntercellular adhesion molecule-1 (ICAM-1)Toll-like receptor 4 (TLR4)

Identifiers

PMID41657055
PMCPMC12969769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.